Albany Molecular Research Inc. (AMRI) is seeking a partner for its 5-HT6 antagonist research program targeting treatments for cognitive impairment in Alzheimer’s disease, schizophrenia and various orphan diseases. AMRI’s novel series of 5-HT6 antagonists demonstrate good drug properties, robust CNS ex vivo receptor occupancy, large safety margins, good off-target profiles and great potential to identify a best in class molecule. A leading candidate compound and multiple back-up compounds are available for advancement.
Cognitive function, which underpins all of our everyday activities, is defined as the complex pattern of mental processes that are involved in attending to, acquiring, storing, retrieving, and manipulating information. There is currently a highly significant unmet need for treating cognitive impairment associated with Alzheimer’s disease, schizophrenia, and several orphan diseases.